Sykehuset i Vestfold HF   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Vestfold Norway (1870)

Organization Overview

First Clinical Trial
2003
NCT00248703
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Sykehuset i Vestfold HF

Active Ingredients

Drugs in Phase 4 Trials (6)

epinephrine (levophed) (1 trial)

levosimendan (1 trial)

pivmecillinam (1 trial)

propofol (diprivan) (1 trial)

sevoflurane (ultane) (1 trial)

sodium chloride (1 trial)

Drugs in Phase 3 Trials (2)

cladribine (leustatin) (1 trial)

rituximab (rituxan) (1 trial)

Drugs in Phase 2 Trials (1)

docetaxel (taxotere) (1 trial)

Drugs in Other Trials (1)

triamcinolone (kenalog) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aneurysm (Phase 4)

Aortic Aneurysm (Phase 4)

Aortic Aneurysm, Abdominal (Phase 4)

Aortic Diseases (Phase 4)

Breast Neoplasms (Phase 2)

Bronchiolitis (Phase 4)

Heart Failure (Phase 4)

Hip Fractures (Phase 4)

Multiple Sclerosis (Phase 3)

Pyelonephritis (Phase 4)

Sclerosis (Phase 3)

Urinary Tract Infections (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 10